心脏再同步治疗:传导系统起搏对比双心室起搏的随机试验
PhysioSync-HF 试验纳入 173 例 HFrEF 合并 LBBB 患者,比较传导系统起搏(CSP)与双心室起搏(BiVP)的 12 个月疗效。结果显示 CSP 未达到非劣效,且在心衰相关复合终点上劣于 BiVP。研究不支持将 CSP 作为该人群一线再同步策略。
要点
- HFrEF 合并 LBBB 患者中,CSP 在 12 个月心衰复合终点上劣于 BiVP。
- CSP 组 12 个月平均 LVEF 为 35%,低于 BiVP 组的 39%。
- 两组 QRS 时限、KCCQ 评分、NYHA 分级和利钠肽水平改善相当。
核心结论
- 在 HFrEF 合并 LBBB 患者中,CSP 在死亡、心衰住院、紧急心衰就诊及 LVEF 变化的复合终点上劣于 BiVP。
研究设计与样本
- PhysioSync-HF 为研究者发起、多中心、非劣效随机临床试验,2022 年 11 月至 2023 年 12 月在巴西 14 家医院入组,随访 12 个月。
- 纳入症状性 HFrEF 成人患者,NYHA II–III 级,LVEF≤35%,LBBB 且 QRS≥130ms,按 1:1 随机分至 CSP 或 BiVP。
主要发现
- 共纳入 173 例患者,中位年龄 62 岁,女性 86 例(49.7%),扩张型心肌病 115 例(66.5%),中位 LVEF 26%,中位 QRS 180ms。
- 死亡、心衰住院或紧急心衰就诊的时间事件复合终点在 CSP 组更高,HR 为 2.35(95%CI 0.99–5.61)。
- 12 个月平均 LVEF:CSP 组 35%(SD 12%),BiVP 组 39%(SD 12%),平均差 3.8%(95%CI 0.3%–7.3%)。
- 两组 QRS 时限、KCCQ 总分、NYHA 分级和利钠肽水平较基线改善程度相当。
关键数值与推荐
- 预设定非劣效界值为 OR 1.2。
- 主要终点为死亡、心衰住院、紧急心衰就诊和 12 个月 LVEF 变化的分层复合终点。
临床怎么用
- 研究结果不支持将 CSP 常规用作 HFrEF 合并 LBBB 患者的一线再同步策略。
- CSP 在本试验中显示更低的 12 个月直接医疗费用,但临床疗效终点劣于 BiVP。
局限性
- CSP 未能达到预设的非劣效性标准。
- 部分次要终点的事件数较少,置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Conduction system pacing (CSP) is a promising and potentially cost-effective alternative to biventricular pacing (BiVP) in patients with heart failure with reduced ejection fraction (HFrEF) and left bundle-branch block (LBBB), but its impact on heart failure (HF) outcomes remains uncertain. OBJECTIVE: To compare CSP vs BiVP on an HF-related outcome in patients with HFrEF and LBBB. DESIGN, SETTING, AND PARTICIPANTS: PhysioSync-HF (Conduction System Pacing Versus Biventricular Resynchronization in Patients With Chronic Heart Failure) was an investigator-initiated, multicenter, noninferiority randomized clinical trial enrolling participants from November 2022 to December 2023 with 12 months of follow-up at 14 hospitals across all regions of Brazil. Adults with symptomatic HFrEF (New York Heart Association NYHA] classes II through III), left ventricular ejection fraction (LVEF) of 35% or less, and LBBB (QRS duration ≥130 milliseconds) were eligible for inclusion. Data were analyzed from May to August 2025. INTERVENTION: Patients were randomized 1:1 to either CSP (preferentially left bundle-branch area pacing) or BiVP. MAIN OUTCOMES AND MEASURES: The primary outcome was a hierarchical composite of death, HF hospitalizations, urgent HF visits, and change in LVEF at 12 months. The prespecified noninferiority margin for the odds ratio (OR) was 1.2. RESULTS: A total of 173 patients (median [IQR] age, 62 years [56-68]; 86 female patients [49.7%]; 115 (66.5%) with dilated cardiomyopathy; median [IQR] LVEF, 26% [22%-31%]; median [IQR] QRS, 180 milliseconds [170-200]) were included. At 12 months, CSP failed to meet noninferiority and was inferior to BiVP for the primary end point (OR, 2.36; 95% CI, 1.37-4.06; P = .99 for noninferiority; P = .002 for between-group difference). The time-to-event composite of death, HF hospitalizations, or urgent HF visits was higher in CSP (hazard ratio, 2.35; 95% CI, 0.99-5.61). Mean (SD) LVEF increased to 35% (12%) with CSP and 39% (12%) with BiVP (mean difference, 3.8%; 95% CI, 0.3%-7.3%). Relative to baseline, both groups had comparable improvements in QRS duration, Kansas City Cardiomyopathy Questionnaire Overall Summary Score, NYHA class, and natriuretic peptide levels. Total direct medical cost related to the procedure and heart failure care was the equivalent of $7090 (95% CI, $5779-$8648) lower in patients randomized to CSP at 12 months. CONCLUSIONS AND RELEVANCE: In patients with HFrEF and LBBB, CSP was inferior to BiVP for a composite of death, HF hospitalizations, urgent HF visits, and change in LVEF at 12 months. These findings do not support the routine use of CSP as the first-line resynchronization strategy in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05572736.
引用
- Zimerman, Dal Forno, Rohde, et al. Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41811324. doi:10.1001/jamacardio.2026.0101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。